AstraZeneca will showcase new data across its Vaccines and Immune Therapies portfolio at the 11th annual IDWeek conference, 19 – 23 October 2022, reinforcing its commitment to deliver long-lasting immunity for millions of people globally. The Company is set to present seven abstracts at the event.
Data featuring Evusheld (tixagevimab and cilgavimab)1-5 and Vaxzevria (ChAdOx1-S [Recombinant], formerly AZD1222)6 in COVID-19 and Beyfortus (nirsevimab), in respiratory syncytial virus (RSV)7 will be presented. Beyfortus has the potential to transform RSV protection as the first and only single-dose preventative option for the broad infant population, including those born healthy, at term, pre-term or with specific medical conditions. In September, Beyfortus received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
Iskra Reic, Executive Vice-President Vaccines and Immune Therapies, AstraZeneca, said: “In our work in Vaccines and Immune Therapies, AstraZeneca has the ambition to help provide long-lasting immunity for millions. This year at IDWeek, our data for Evusheld, our long-acting antibody for patients at high risk of hospitalisation and death from COVID-19, and Beyfortus, our investigational long-antibody for RSV, demonstrate our commitment to helping protect the most vulnerable, ensuring no one is left behind.”
Evusheld’s role in protecting against COVID-19
Data from three abstracts from the Phase III TACKLE trial of Evusheld in adults with mild to moderate COVID-19 will be presented, which include new analyses on the prevention of hospitalisation and death;1 reduction in the severity and progression of COVID-19 symptoms;2 and the susceptibility of treatment-emergent viral variants to Evusheld.3 Data on the activity of Evusheld against circulating SARS-CoV-2 variants and those identified in the Phase III PROVENT prophylaxis trial will also be presented.
Pursuing a breakthrough in infant RSV care
New viral susceptibility data on Beyfortus data in infants up to 150 days post-dose will be presented during IDWeek.7 Beyfortus is the first investigational passive immunisation with the potential to help protect a broad infant population across the entire RSV season with a single dose.
Additional data on Vaxzevria
AstraZeneca will also present data on Vaxzevria, evaluating its impact on immune responses, viral shedding and symptom burden in breakthrough SARS-CoV-2 infection.
